论文信息 - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. - 字舞流文

Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer.

S. Piha-Paul | I. Mayer | M. Arnedos | C. Saura | R. Cutler | I. Spanggaard | L. Smyth | D. Hyman | J. Lu | A. Brufksy | J. Lu